Prostaglandin D2-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study

Table 2 PGD ₂ ratios

Trigger	Control	MCAD	MCAS	SM	MCAD-M	MCAD + M
Trigger	Median ratio (range)	Median ratio (range)	Median ratio (range)	Median ratio (range)	Median ratio (range)	Median ratio (range)
AA	1.43	1.13**	1.15**	1.07	1.17*	1.11*
AA	(0.88-2.46)	(0.20-3.26)	(0.63-1.63)	(0.20-3.26)	(0.63-1.63)	(0.20-3.26)
ASA	1.10	1.10	1.16	1.03	1.18	1.03
ASA	(0.93-1.45)	(0.21-3.30)	(0.57-2.65)	(0.21-3.30)	(0.57-2.65)	(0.21-3.30)
SP	0.88	2.05***	1.71**	2.56***	2.07***	2.04***
SP	(0.40-1.34)	(0.79-6.64)	(0.79-4.87)	(1.61-6.64)	(0.99-4.87)	(0.79-6.64)

PGD₂ ratio: PGD₂ release from PBLs in the presence of a trigger, divided by basal PGD₂ release. Control: healthy individuals (n = 10); MCAD: patients suffering from mast cell activation disease (n = 22); MCAS: MCAD patients with mast cell activation syndrome (n = 12); SM: MCAD patients with systemic mastocytosis (n = 10); MCAD-M: MCAD patients without MCAD-specific medication (n = 9); MCAD + M: MCAD patients with MCAD-specific medication (n = 13). Significantly different from control: ***P < 0.001, **P < 0.01, *P < 0.05, Mann–Whitney U test.

ISSN: 1479-5876